Drug Innovations Are Delivering for Patients. We Need Innovation in How They’re Paid For.
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
Biopharmaceutical companies produce lifesaving innovations such as COVID-19 vaccines that improve patient health and bring value to society broadly. But patients will only benefit from these innovations if they can access them.
We need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines, NPC President and CEO John M. O’Brien, PharmD, MPH, writes in a commentary for PharmaBoardroom.
Our focus should always be on what works best for the patient. ... We must find new ways to make sure patients have access to treatments.
The biopharmaceutical industry is innovating every day to create new medicines to help patients live longer, heathier lives, but poorly designed health insurance is creating barriers for patients in accessing high-value drugs, Dr. O’Brien explains.
“Our focus should always be on what works best for the patient,” he writes. “We must find new ways to make sure patients have access to treatments.”
View the full commentary on reforming health benefits on the PharmaBoardroom website.
